varlitinib
Small moleculeexperimental
Clinical trial activity
21 trials · 9 clinical orgs · 0 marketing orgs
Phase 1
13
Phase 2
11
Phase 3
2
Phase 4
0
Earliest trial started Jan 1, 2006 (NCT00278902)
Timeline
Indications
Mechanism of action
EGFR inhibitor
Also ERBB4 inhibitor
ERBB2 inhibitor
Also ERBB4 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1- Mol. weight
- 466.95 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2103842 ↗
Also known as
- arry-334543
- arry-334543
- arry-334543
- arry-543
- arry-543
- aslan001
- aslan-001
- aslan-001
- varlitinib
- varlitinib
- varlitinib
- varlitinib
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05400915 | Phase 1/Phase 2 (Phase 2) | Jul 23, 2019 | Yonsei University |
| NCT03231176 | Phase 2 | Dec 19, 2017 | Aslan Pharmaceuticals |
| NCT03368846 | Phase 1 | Nov 23, 2017 | Aslan Pharmaceuticals |
| NCT03130790 | Phase 2/Phase 3 (Phase 3) | Sep 1, 2017 | Aslan Pharmaceuticals |
| NCT03093870 | Phase 2/Phase 3 (Phase 3) | Jul 4, 2017 | Aslan Pharmaceuticals, bioRASI, LLC, CMIC Co, Ltd. Japan, Syneos Health |
| NCT03129074 | Phase 2 | Jul 1, 2017 | Aslan Pharmaceuticals |
| NCT03499626 | Phase 1/Phase 2 (Phase 2) | May 5, 2017 | National University of Singapore |
| NCT03082053 | Phase 1 | Jan 31, 2017 | Aslan Pharmaceuticals |
| NCT02992340 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2016 | Aslan Pharmaceuticals |
| NCT07166367 | Phase 2 | Aug 11, 2016 | Government of Singapore |
| NCT02609958 | Phase 2 | Oct 1, 2015 | Aslan Pharmaceuticals |
| NCT02396108 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2015 | National University of Singapore |
| NCT02338245 | Phase 2 | Dec 1, 2014 | Aslan Pharmaceuticals |
| NCT02648425 | Phase 1 | Aug 1, 2014 | Aslan Pharmaceuticals |
| NCT02435927 | Phase 1 | Aug 1, 2014 | Aslan Pharmaceuticals, Government of Singapore |
| NCT01614522 | Phase 2 | Mar 1, 2012 | Aslan Pharmaceuticals, Seoul National University |
| NCT00862524 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2009 | Array BioPharma |
| NCT00833326 | Phase 1 | Jan 1, 2009 | Array BioPharma |
| NCT00710736 | Phase 1 | Jun 1, 2008 | Array BioPharma |
| NCT00637702 | Phase 1 | Feb 1, 2008 | Array BioPharma |
Showing 20 of 21 trials
Page 1 / 2
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aslan Pharmaceuticals | For profit | 12 | 11 | 3 | 2012 |
| Array BioPharma | For profit | 5 | 5 | 2 | 2006 |
| Government of Singapore | Government | 2 | 2 | 2 | 2014 |
| National University of Singapore | Academic/Hospital | 2 | 2 | 1 | 2015 |
| bioRASI, LLC | For profit | 1 | 0 | 1 | 2017 |
| CMIC Co, Ltd. Japan | For profit | 1 | 0 | 1 | 2017 |
| Seoul National University | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Syneos Health | For profit | 1 | 0 | 1 | 2017 |
| Yonsei University | Academic/Hospital | 1 | 1 | 1 | 2019 |
9 organizations
Page 1 / 1